Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and making regular contributions to a retirement account, allowing the power of compounding to work its magic over time.
Nevertheless, there is an undeniable appeal in the search for potential multibagger supplies. There’s something compelling about companies with disruptive innovations, whose shares could be on the cusp of rapid growth and capable of delivering life-changing returns for shareholders.
Recursion pharmaceutical products (NASDAQ: RXRX) is a clinical-stage biotech that may have that potential. The company uses artificial intelligence (AI) for drug discovery and promises to revolutionize medicine. Let’s see if buying the stock can ultimately help you become a millionaire.
Recursion has quickly established itself as a leader in AI-enabled biotechnology. The company’s BioHive-2 supercomputer, powered by Nvidia AI chips are one of the world’s most powerful accelerated computing systems.
Via advanced machine learning techniques, BioHive-2 analyzes vast amounts of biological data to identify drug targets, including proteins and genes involved in diseases. Recursion’s operating system (OS) evaluates millions of compounds to identify potential drug candidates, while also predicting drug molecule properties and optimal patient populations to improve drug design.
These efforts enable accelerated research into treatments for a wide range of conditions while reducing costs compared to traditional methods.
A major development for Recursion this year was its merger with Exscientia, another biotech company focused on AI-based drug discovery. Exscientia’s expertise in advanced chemical design methods complements Recursion’s biology-driven approach. This combination has created a vertically integrated platform, which has resulted in a fundamentally stronger company.
The good news is that Recursion’s technology has already shown promising results, with a robust pipeline of drug candidates now spanning Exscientia’s existing programs.
One of the most promising prospects is REC-994, which could become the first oral therapy for the treatment of symptomatic cerebral cavernous malformation (CCM), a brain bleeding disorder for which there are currently no approved treatments.
REC-617 has also shown encouraging results, with a recent Phase 1 interim study demonstrating positive patient responses and good tolerability in the treatment of advanced solid tumors. The company believes this drug has “best in class” potential, one of the many reasons that make Recursion an intriguing opportunity for investors.